Next-Generation Lipids in RNA Interference Therapeutics

RNA is emerging as a potential therapeutic modality for the treatment of incurable diseases. Despite intense research, the advent to clinical utility remains compromised by numerous biological barriers, hence, there is a need for sophisticated delivery vehicles. In this aspect, lipid nanoparticles (...

Full description

Saved in:
Bibliographic Details
Published in:ACS nano Vol. 11; no. 8; pp. 7572 - 7586
Main Authors: Rietwyk, Stephanie, Peer, Dan
Format: Journal Article
Language:English
Published: United States American Chemical Society 22.08.2017
Subjects:
Animals
Cations - chemistry
Gene Silencing - physiology
Humans
Lipids - chemistry
Nanoparticles - chemistry
RNA Interference - physiology
RNA, Small Interfering - genetics
RNA, Small Interfering - physiology
toxicity
RNAi therapeutics
lipidoids
delivery
lipid nanoparticles
RNA interference
cationic lipids
ionizable amino lipids
gene silencing
siRNA
ISSN:1936-0851, 1936-086X, 1936-086X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:RNA is emerging as a potential therapeutic modality for the treatment of incurable diseases. Despite intense research, the advent to clinical utility remains compromised by numerous biological barriers, hence, there is a need for sophisticated delivery vehicles. In this aspect, lipid nanoparticles (LNPs) are the most advanced platform among nonviral vectors for gene delivery. In this review, we critically review the literature and the reasons for ineffective delivery beyond the liver. We discuss the toxicity issues associated with permanently charged cationic lipids and then turn our attention to next-generation ionizable cationic lipids. These lipids exhibit reduced toxicity and immunogenicity and undergo ionization under the acidic environment of the endosome to release the encapsulated payload to their site of action in the cytosol. Finally, we summarize recent achievements in therapeutic nucleic acid delivery and report on the current status of clinical trials using LNP and the obstacles to clinical translation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1936-0851
1936-086X
1936-086X
DOI:10.1021/acsnano.7b04734